

Granules India

Estimate change	↑
TP change	↑
Rating change	↔

CMP: INR706 TP: INR820 (+16%) Buy

FDF/API/CDMO drive earnings

Scaling CDMO/complex generics to better business prospects

- Granules India (GRAN) delivered in-line revenue and higher-than-expected EBITDA/PAT (6% beat) for the quarter. Higher formulation (FDF) and API sales led to improvement in overall momentum for the quarter.
- Effectively, GRAN ended FY26 on a strong note after muted performance over FY23-25. This was on the back of increased formulation (FD) sales and product diversification to the complex generics segment.
- Geographically, Europe's scale-up (+49% YoY Ex-Senn chemicals in 4Q) was due to the launch of complex generics and expanding dossiers.
- The complex generics revenue share has increased considerably from 39% YoY to 46% for 4QFY26. Accordingly, the integrated generics' share reduced from 57% of sales to 50% of sales in 4QFY26.
- GRAN is enhancing prospects in the CDMO segment by integrating R&D at the Zurich and India sites and scaling up manufacturing. Notably, it has achieved EBITDA break-even in the acquired Senn Chemicals business in 4QFY26.
- We raise our earnings estimate by 3%/6% for FY26/FY27, factoring in: 1) the scale-up, driving EBITDA margin expansion of the CDMO peptide business, 2) scale-up of the ADHD portfolio/controlled substances in the US, and 3) the rollout of complex generics and speciality products. We value GRAN at 21x 12M forward earnings to arrive at our TP of INR820. Reiterate BUY.

Product mix/operating leverage drive margins

- GRAN's 4QFY26 sales grew 22.8% YoY to INR14.7b (our est. of INR14.5b), steady momentum in FDF sales/strong growth in API.
- Gross margin (GM) expanded 230bp to 65.7% due to better product mix.
- EBITDA margin expanded 290bp YoY to 24% (our est. of 23%) due to higher gross profit. Higher employee cost (+220bp YoY as % of sales) was offset by lower other expenses (down 275bp as % of sales).
- EBITDA grew by 39.5% YoY to INR3.5b (our est. of INR3.3b) for the quarter.
- Exceptional item in 4QFY26 pertains to gains related to the disposal of investment.
- Adjusted PAT grew by 47.5% YoY to INR1.9b (our estimate: INR1.8b).
- For FY26, Revenue/EBITDA/PAT grew 19.7%/25.4%/26.2% to INR53.6b/INR11.8b/INR6b.

FDF leads momentum/API surges, while CDMO witnesses a sharp QoQ spike

- FDF sales grew 15.5% YoY to INR10.7b (76% of sales).
- Intermediate (PFI) sales grew 8.8% YoY to INR1.3b (10% of sales).
- API sales grew 33.2% YoY to INR2b (14% of sales).
- CDMO sales grew 114% QoQ to INR699m (5% of sales).

Bloomberg	GRAN IN
Equity Shares (m)	243
M.Cap.(INRb)/(USD\$)	174.6 / 1.8
52-Week Range (INR)	731 / 431
1, 6, 12 Rel. Per (%)	7/31/55
12M Avg Val (INR M)	658

Financials & Valuations (INRb)

Y/E MARCH	FY26	FY27E	FY28E
Sales	53.7	62.7	73.0
EBITDA	11.9	14.4	16.9
Adj. PAT	6.0	7.8	9.7
EBIT Margin (%)	16.6	17.6	18.3
Cons. Adj. EPS (INR)	24.3	31.5	39.0
EPS Gr. (%)	26.2	29.6	23.7
BV/Sh. (INR)	205.2	235.6	273.5

Ratios

Net D:E	0.3	0.2	0.2
RoE (%)	13.7	14.3	15.3
RoCE (%)	11.7	12.5	13.6
Payout (%)	4.9	3.7	3.0

Valuations

P/E (x)	29.0	22.4	18.1
EV/EBITDA (x)	14.5	12.0	10.1
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	2.4	-0.2	2.6
EV/Sales (x)	3.2	2.8	2.3

Shareholding Pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	38.0	38.8	38.8
DII	17.0	17.5	22.4
FII	15.3	13.6	15.2
Others	29.7	30.2	23.6

FII includes depository receipts

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Eshita Jain - Research Analyst (Eshita Jain @MotilalOswal.com) | **Vipul Mehta** (vipul.mehta@motilalosal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilalosal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- The GPI facility in Virginia reached optimal utilization, with ongoing capacity expansion/new distribution center strengthening future growth visibility in the US market.
- GRAN has submitted all action points with respect to remediation measures at the Gagillapur site. The corrective actions were largely completed by Mar'26, and the company awaits USFDA re-inspection.
- The CDMO business, through Senn Chemicals, garnered revenue of INR1.6b in FY26 and achieved EBITDA breakeven in 4QFY26.
- Infrastructure ramp-up is underway across geographies for the CDMO business, including the Zurich site upgrade. Notably, Hyderabad R&D center has become fully operational to support Zurich business activities. This would be further supported by the API manufacturing unit at Zurich and intermediates manufacturing in India.
- Nine ANDA approvals are pending from the Gagillapur site, supporting potential US product launches.

Quarterly Earning Model

Y/E March	FY25				FY26				FY25	FY26	FY26E	Var.
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	vs Est
Net Sales	11,799	9,666	11,377	11,974	12,101	12,970	13,879	14,706	44,816	53,656	14,469	1.6
YoY Change (%)	19.7	-18.7	-1.5	1.8	2.6	34.2	22.0	22.8	-0.5	19.7	20.8	
Total Expenditure	9,206	7,633	9,074	9,451	9,634	10,188	10,799	11,185	35,364	41,805	11,155	
EBITDA	2,593	2,033	2,303	2,524	2,467	2,782	3,081	3,521	9,452	11,851	3,313	6.3
YoY Change (%)	64.2	-4.5	-8.1	-1.3	-4.8	36.8	33.8	39.5	7.8	25.4	31.3	
Margins (%)	22.0	21.0	20.2	21.1	20.4	21.5	22.2	23.9	21.1	22.1	22.9	
Depreciation	529	525	566	635	688	720	735	817	2,255	2,961	740	
EBIT	2,064	1,508	1,737	1,889	1,779	2,062	2,346	2,704	7,197	8,890	2,573	
YoY Change (%)	90.0	-6.0	-12.3	-6.7	-13.8	36.7	35.1	43.2	7.5	23.5	36.2	
Margins (%)	17.5	15.6	15.3	15.8	14.7	15.9	16.9	18.4	16.1	16.6	17.8	
Interest	270	257	266	240	238	292	287	327	1,032	1,144	283	
Other Income	21	32	57	19	163	-11	-36	88	129	203	36	
PBT before EO expense	1,814	1,284	1,528	1,668	1,704	1,759	2,022	2,464	6,294	7,950	2,326	
Extra-Ord expense	0	0	0	-308	259	0	0	-159	-308	100	0	
PBT	1,814	1,284	1,528	1,976	1,445	1,759	2,022	2,624	6,601	7,850	2,326	
Tax	468	311	352	455	319	453	520	608	1,587	1,900	547	
Rate (%)	25.8	24.3	23.0	23.0	22.1	25.7	25.7	23.2	24.0	24.2	23.5	
(Profit)/Loss of JV/Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	1,346	972	1,176	1,520	1,126	1,306	1,502	2,016	5,015	5,950	1,780	
Adjusted PAT	1,346	972	1,176	1,284	1,328	1,306	1,502	1,893	4,778	6,030	1,780	6.4
YoY Change (%)	112.7	-4.8	-6.4	-1.0	-1.4	34.3	27.7	47.5	13.6	26.2	38.6	
Margins (%)	11.4	10.1	10.3	10.7	11.0	10.1	10.8	12.9	10.7	11.2	12.3	

E: MOFSL Estimates

**Key performance Indicators
(Consolidated)**

Y/E March	FY25				FY26				FY25	FY26	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			
FD	8,912	7,490	8,674	9,259	8,989	9,657	10,548	10,691	34,335	39,893	10,926
YoY Change (%)	64.4	1.6	13.7	7.1	0.9	28.9	21.6	15.5	18.0	16.2	18.0
PFI	997	756	1,309	1,232	1,194	1,331	1,481	1,341	4,294	5,347	1,441
YoY Change (%)	-32.6	-47.0	-24.5	-16.9	19.8	76.1	13.1	8.8	-29.7	24.5	17.0
API	1,890	1,420	1,393	1,483	1,627	1,705	1,515	1,975	6,186	6,822	1,602
YoY Change (%)	-36.1	-52.2	-36.6	-9.2	-13.9	20.1	8.8	33.2	-37.0	10.3	8.0
Cost Break-up											
RM Cost (% of Sales)	41.1	38.0	38.3	36.6	35.1	34.3	36.1	34.3	61.5	65.0	35.8
Staff Cost (% of Sales)	13.9	16.5	14.7	14.1	16.8	16.9	16.3	16.4	14.7	16.6	15.5
Other Cost (% of Sales)	23.1	24.5	26.7	28.2	27.7	27.3	25.4	25.4	25.7	26.4	25.8
Gross Margins(%)	58.9	62.0	61.7	63.4	64.9	65.7	63.9	65.7	38.5	35.0	64.2
EBITDA Margins(%)	22.0	21.0	20.2	21.1	20.4	21.5	22.2	23.9	21.1	22.1	22.9
EBIT Margins(%)	17.5	15.6	15.3	15.8	14.7	15.9	16.9	18.4	16.1	16.6	17.8




Key highlights from the management commentary

- API segment growth for the quarter was led by new product launches/backward integration into formulations.
- There has been no meaningful pricing tailwinds in key molecules like paracetamol/metformin currently. GRAN continues to monitor rising raw material prices, inventory available, and the scope of passing the increase in RM prices to customers.
- Gross margin expanded ~355bp YoY to ~65% in FY26, supported by an improved mix toward complex generics and value-added formulations.
- DCDA production is largely stabilized. GRAN is optimizing cost of production, considering the reduction of prices by Chinese competitors.
- FY27 capex would be ~INR6b, broadly allocated across API capacity/US project/IT investments. The company continues focus on building front-end and supply chain capabilities.
- Remediation expenses are expected to taper meaningfully from FY27 onward.
- Net debt is likely to remain stable in FY27.
- Overall, GRAN has filed 6 ANDAs with USFDA, 3 filings with EU health regulatory authority, and 1 filing with the Canadian regulatory authority.
- The cash conversion cycle was moderated due to capital build-up for new launches.
- Net debt stood at INR4b, and Net Debt to EBITDA at 0.34x.
- R&D for 4QFY26 stood at INR781m, 5.3% of sales.


Key exhibits

Exhibit 1: Revenue grew 23% YoY in 4QFY26



Source: MOFSL, Company

Exhibit 2: EBITDA margin expanded 290bp YoY in 4QFY26



Source: MOFSL, Company

Enhancing offerings and increasing market presence to improve growth prospects

Peptide push/rising complex generics mix to drive the next phase of growth

- GRAN delivered FDF sales of 16% YoY/15% YoY in FY26/4QFY26.
- Notably, the FDF share in FY26 revenue was 74%, driven by the scale-up of the ADHD portfolio.
- The complex generics segment's share has significantly scaled up to 46% in 4QFY26 vs 39% in 4QFY25. Notably, GRAN's focus has shifted to high-value/complex therapies over the medium-to-long term.
- The peptide CDMO emerged as a revenue pillar, delivering EBITDA breakeven in 4QFY26.
- Notably, the emerging peptide CDMO platform adds a new growth lever, while the core integrated generics business continued to provide stability.
- GRAN plans to add 1-2-products in the controlled substance category as part of its complex generics portfolio annually over the next 2-3 years.
- We expect a 15% sales CAGR in the FDF segment over FY26-28 to reach INR52.8b.

Gagillapur re-inspection outcome awaited /Genome Valley scale up to fuel growth


- During FY26, regulatory inspections across key sites indicated a clear improvement in compliance standards.
- Gagillapur post warning letter remediation remains on track, with USFDA meeting concluded in Jan'26 and responses submitted in Feb'26. Approvals for nine ANDAs from the site are contingent on this outcome.
- The Genome Valley (GLS facility) received a VAI, suggesting observations were manageable with no major regulatory concerns.
- The Chantilly facility underwent routine inspection by USFDA between Mar and Apr'26, resulting in 4 Form 483 observations, without any data integrity issues. Responses were submitted within stipulated timelines.
- Importantly, the Virginia facility completed its inspection with zero observations, underscoring strong compliance execution.

- Collectively, these developments reflect material progress in strengthening regulatory compliance and transitioning towards a more stable and audit-ready operating environment.

Reiterate BUY


- We raise our earnings estimate by 3%/6% for FY26/FY27, factoring in: 1) the scale-up, driving EBITDA margin expansion of the CDMO peptide business, 2) scale-up of the ADHD portfolio/controlled substances in the US, and 3) the rollout of complex generics and speciality products.
- We value GRAN at 21x 12M forward earnings to arrive at our TP of INR820. Reiterate BUY.

Exhibit 3: P/E chart



Source: MOFSL, Company, Bloomberg


Exhibit 4: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg


Story in charts

Exhibit 5: Expect a revenue CAGR of ~17% over FY26-28




Source: MOFSL, Company

Exhibit 6: EBITDA margin to expand 100bp over FY26-28




Source: MOFSL, Company

Exhibit 7: Expect FD to increase to 78% in FY28




Source: MOFSL, Company

Exhibit 8: FDF sales to clock a 21% CAGR over FY26-28




Source: MOFSL, Company

Exhibit 9: PAT to exhibit a 27% CAGR over FY26-28



Source: MOFSL, Company

Exhibit 10: Return ratios in an uptrend over FY26-28



Source: MOFSL, Company

Financials and valuations

Consolidated - Income Statement

	INRm						
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	37,477	45,119	45,063	44,816	53,656	62,723	72,989
Change (%)	15.8	20.4	-0.1	-0.5	19.7	16.9	16.4
Total Expenditure	30,427	35,901	36,293	35,364	41,805	48,360	56,128
% of Sales	81.2	79.6	80.5	78.9	77.9	77.1	76.9
EBITDA	7,050	9,218	8,770	9,452	11,851	14,364	16,860
Margin (%)	18.8	20.4	19.5	21.1	22.1	22.9	23.1
Depreciation	1,586	1,845	2,073	2,255	2,961	3,327	3,482
EBIT	5,464	7,373	6,697	7,197	8,890	11,037	13,378
Int. and Finance Charges	232	559	1,058	1,032	1,144	1,103	1,041
Other Income	176	138	44	129	203	238	277
PBT bef. EO Exp.	5,407	6,952	5,683	6,294	7,950	10,172	12,614
EO Items	173	-80	-211	308	-100	0	0
PBT after EO Exp.	5,580	6,872	5,472	6,601	7,850	10,172	12,614
Current Tax	1,382	1,772	1,652	1,828	1,961	2,360	2,952
Deferred Tax	70	-66	-233	-242	-62	0	0
Tax Rate (%)	26.0	24.8	25.9	24.0	24.2	23.2	23.4
Add: Associate income	0	0	0	0	0	0	0
Reported PAT	4,128	5,166	4,052	5,015	5,950	7,812	9,662
Adjusted PAT	4,000	5,224	4,207	4,778	6,030	7,812	9,662
Change (%)	-27.6	30.6	-19.5	13.6	26.2	29.6	23.7
Margin (%)	10.6	11.5	9.3	10.6	11.2	12.4	13.2

Consolidated - Balance Sheet

	INRm						
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	248	242	242	243	248	248	248
Total Reserves	25,617	28,107	32,013	36,913	50,602	58,124	67,522
Net Worth	25,865	28,349	32,255	37,156	50,850	58,372	67,770
Minority Interest	6	0	0	0	0	0	0
Deferred Liabilities	139	77	231	314	370	370	370
Total Loans	10,928	11,362	13,151	14,548	15,120	14,290	13,460
Capital Employed	36,938	39,788	45,637	52,017	66,341	73,033	81,601
Gross Block	25,355	30,897	34,817	40,381	51,462	55,846	60,229
Less: Accum. Deprn.	9,943	11,788	13,861	16,116	19,078	22,404	25,886
Net Fixed Assets	15,412	19,109	20,956	24,265	32,384	33,441	34,343
Capital WIP	3,562	2,394	2,717	4,402	4,095	5,018	5,839
Total Investments	197	361	382	426	228	228	228
Curr. Assets, Loans&Adv.	25,945	27,168	30,783	32,755	39,737	46,219	55,057
Inventory	9,786	11,494	13,005	13,428	16,730	17,886	20,760
Account Receivables	9,250	9,485	9,858	9,422	9,094	14,951	17,397
Cash and Bank Balance	4,095	3,128	3,864	5,964	9,491	7,110	9,601
Loans and Advances	2,815	3,060	4,056	3,941	4,422	6,272	7,299
Curr. Liability & Prov.	8,191	9,258	9,573	10,509	10,859	12,629	14,621
Account Payables	6,386	7,821	7,495	7,261	6,728	10,334	11,995
Other Current Liabilities	1,294	998	1,580	2,614	3,107	1,882	2,190
Provisions	511	439	497	634	1,023	412	437
Net Current Assets	17,753	17,910	21,211	22,247	28,878	33,591	40,436
Appl. of Funds	36,938	39,788	45,637	52,017	66,340	73,033	81,600

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
EPS	16.1	21.1	17.0	19.3	24.3	31.5	39.0
Cash EPS	22.5	29.2	25.9	29.0	36.3	44.9	53.0
BV/Share	104.3	117.1	133.1	153.2	205.2	235.6	273.5
DPS	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Payout (%)	7.0	5.5	7.0	5.7	4.9	3.7	3.0
Valuation (x)							
P/E	43.7	33.5	41.6	36.6	29.0	22.4	18.1
Cash P/E	31.3	24.2	27.2	24.3	19.5	15.7	13.3
P/BV	6.8	6.0	5.3	4.6	3.4	3.0	2.6
EV/Sales	4.6	3.9	3.9	3.9	3.2	2.8	2.3
EV/EBITDA	24.5	18.9	20.0	18.4	14.5	12.0	10.1
Dividend Yield (%)	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Return Ratios (%)							
RoE	16.8	19.3	13.9	13.8	13.7	14.3	15.3
RoCE	12.6	14.8	11.7	11.5	11.7	12.5	13.6
RoIC	15.1	17.6	13.7	13.7	14.4	15.0	16.2
Working Capital Ratios							
Asset Turnover (x)	1.0	1.1	1.0	0.9	0.8	0.9	0.9
Inventory (Days)	86	86	99	108	103	101	97
Debtor (Days)	82	76	78	79	63	70	81
Creditor (Days)	71	72	77	76	61	64	73
Leverage Ratio (x)							
Current Ratio	3.2	2.9	3.2	3.1	3.7	3.7	3.8
Interest Cover Ratio	24	13	6	7	8	10	13
Debt/Equity	0.4	0.4	0.4	0.4	0.3	0.2	0.2

Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	5,580	6,952	5,472	4,272	5,358	10,172	12,614
Depreciation	1,586	1,845	2,073	1,462	1,645	3,327	3,482
Interest & Finance Charges	232	559	1,058	628	614	865	764
Direct Taxes Paid	-1,450	-1,758	-1,903	-908	-1,520	-2,360	-2,926
(Inc)/Dec in WC	-2,572	-103	-2,463	2,570	322	-7,093	-4,354
CF from Operations	3,376	7,495	4,238	8,024	6,420	4,910	9,580
Others	-56	-27	156	203	13	0	0
CF from Operating incl EO	3,321	7,467	4,394	8,227	6,433	4,910	9,580
(inc)/dec in FA	-3,967	-4,107	-3,788	-2,109	-2,521	-5,306	-5,205
(Pur)/Sale of Investments	0	2,035	159	0	0	0	0
Others	166	158	28	-3,416	-7,811	238	277
CF from Investments	-3,801	-1,914	-3,602	-5,524	-10,332	-5,068	-4,928
Issue of Shares	37	-3,084	32	50	3,019	0	0
(Inc)/Dec in Debt	2,530	-600	1,435	-2,422	-1,207	-830	-830
Interest Paid	-242	-533	-1,027	-571	-539	-1,103	-1,041
Dividend Paid	-372	-186	-363	-364	-364	-290	-290
CF from Fin. Activity	1,900	-4,403	77	-3,399	4,444	-2,223	-2,161
Inc/Dec of Cash	1,419	1,151	869	-696	545	-2,381	2,491
Opening Balance	2,711	4,095	3,128	3,863	5,964	9,491	7,110
FX	-35	-2,118	-134	2,796	2,982	0	0
Closing Balance	4,095	3,128	3,863	5,964	9,491	7,110	9,601

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online-reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Mital Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Mital Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.mitaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj

Agarwal, Email Id: na@mitaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@mitaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@mitaloswal.com
Mr. Ajay Menon	022 40548083	am@mitaloswal.com

Registration details of group entities: Mital Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Mital Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@mitaloswal.com. In case of grievances for any of the services rendered by Mital Oswal Financial Services Limited (MOFSL) write to grievances@mitaloswal.com, for DP to dpgrievances@mitaloswal.com.